key: cord-1026019-b6grfmpe
authors: Vellere, Iacopo; Graziani, Lucia; Tilli, Marta; Mantella, Antonia; Campolmi, Irene; Mencarini, Jessica; Borchi, Beatrice; Spinicci, Michele; Antonelli, Alberto; Rossolini, Gian Maria; Bartoloni, Alessandro; Zammarchi, Lorenzo
title: Strongyloidiasis in the COVID era: a warning for an implementation of the screening protocol
date: 2021-05-10
journal: Infection
DOI: 10.1007/s15010-021-01621-w
sha: fde350a207a546556ec21a35b0a7cecde47eae0d
doc_id: 1026019
cord_uid: b6grfmpe

nan

We read with extreme interest the recent case report by Marchese et al. concerning the manifestation of Strongyloides stercoralis infection during immunosuppressive therapy for COVID-19 [1] . As a matter of fact, dexamethasone has clearly shown to reduce mortality for COVID-19 in a randomized clinical trial [2] . More recently, international trials showed a benefit in terms of survival with the use of IL-6 antagonists, such as tocilizumab and sarilumab [3, 4] . Moreover, additional treatment options, such as higher dose of corticosteroids and other immunosuppressive drugs, are being evaluated in clinical trials, used off-label or in the context of compassionate programs [5] . The risk of reactivation of latent infections in COVID-19 patients treated with such medications may be considered limited if compared to that of patients with chronic immune-mediated diseases, since treatment course is usually shorter. However, no specific studies have addressed this point so far.

Migrants can harbor latent infections, at risk of reactivation during immunosuppressive conditions, which are widely neglected by physicians working in high-income countries, causing difficulties in screening, diagnosis and management. The guidelines from the Italian and Spanish Societies of Tropical Medicine and Rheumatology have identified some priority infectious diseases to be screened for in migrant candidates for treatment with immunosuppressive biological agents. In addition to HIV, HBV, HCV and latent tuberculosis infection (LTBI), taken into account in several other recommendations, the panel especially recommends screening for strongyloidiasis and Chagas disease in all patients coming from endemic areas [6] . In particular, screening for strongyloidiasis using serology and (if available) stool examination is suggested in exposed populations candidate to biological treatment, while serological screening for Chagas disease should be considered in patients coming from or whose mother was born in continental Latin America and/or in those who received blood transfusions in endemic areas. Major concerns exist about the risk of Strongyloides hyperinfection and dissemination: indeed, corticosteroids can have a hormone-like stimulating effect on larvae growth, just after a single dose [7] . Unfortunately, a case of disseminated strongyloidiasis linked to COVID-19 therapy has already been reported, indicating that this issue should be urgently considered within COVID-19 guidelines [8] .

A screening protocol for infectious diseases, namely LTBI (migrants, elderly people and everyone who was treated with immunosuppressive drugs), strongyloidiasis (migrants from endemic countries and Italian patients older than 65), HBV infection (all subjects) and Chagas disease (migrants from Latin America), in COVID-19 patients potentially candidate to immunosuppressant treatments, was implemented in Careggi University Hospital, Florence, Italy. Screening for LTBI was based on an interferon gamma release assay, while for the remaining infections was based on specific serologycal tests. If possible, subjects at risk for strogyloidiasis were also tested with agar plate stool culture. Overall, one hundred hospitalized COVID-19 patients were screened for latent infections between March and August, 2020. Median age was 67.5 year (IQR 56-78), male to female ratio was 1.4:1. Six patients were migrants from Latin America (n = 5) The patient was a 59-year-old Italian-born subject from a Southern region, typically believed to be at low risk for Strongyloides: prevalence of strongyloidiasis in Italy is unknown, however at least Northern Regions were notoriously endemic in the past. A recent report from these regions underlines its presence in elderly people (born before 1952), with an 8% prevalence among those with eosinophilia and 1% among those with a normal eosinophils count [9] . Regarding migrants, a systematic review showed a strongyloidiasis seroprevalence of 12.2% in non-endemic countries, with the highest rate in subjects coming from East Asia and the Pacific (17.3%), Sub-Saharan Africa (14.6%) and Latin America and the Caribbean (11.6%) [10] . According to another study performed in Italy, a strongyloidiasis seroprevalence of 2.5 and 1.3% was detected in migrants coming from Eastern Europe and North Africa, respectively [11] . Guidelines for screening and management of strongyloidiasis in non-endemic countries suggest that all candidates to immunosuppressive treatments at high or intermediate risk of exposure to Strongyloides, should be screened with both direct (agar plate stool culture or Baermann technique) and indirect methods (serology); in case of lack of adequate diagnostic facilities, empirical treatment with a single dose of ivermectin for one or two days is recommended [12] . Therefore, in hospitalized patients with COVID-19 a first screening strategy for strongyloidiasis could consist of testing migrants, patients exposed in tropical and subtropical regions and patients aged over 65 from areas where the disease was endemic in the past, such as the Mediterranean basin. The screening should be performed with both serology and direct examination of stools using a more sensitive technique (Baermann, agar plate stool culture or even Polymerase Chain Reaction, PCR). However, this strategy has some limitations: tests are time and resource consuming (agar plate stool culture takes at least 48 h to turn out positive) and serology could be falsely negative in immunocompromised subjects. Moreover, stool sample could be difficult to collect, and larvae are identified only by experienced parasitologists.

An alternative to the "test and treat" strategy could be based on the presumptive treatment of the target population with a single dose of ivermectin for one day, regardless of laboratory results, as recently suggested by Stauffer et al. [13] . This approach is also suggested by guidelines for management of solid-organ transplant recipients and donors in Latin America [14] : in hyperendemic regions where ivermectin is easily accessible, empiric treatment of all candidates (and donors) before transplant is suggested, without screening because of the risk of false negative testing. The guidelines advocate that optimal strategy depends on local epidemiology, laboratory capabilities, and drug availability.

This approach could be more pragmatic, but may present logistic drawbacks depending on the setting:in several countries, like Italy, ivermectin is unregistered and should be imported from abroad resulting in uncertain drug supplying, especially in peripheral centers [15] . Legislation in Italy requires a signed informed consent to dispense foreign drugs, and this may cause an additional barrier in elderly people with cognitive impairment or non-Italian speaking migrants; finally, Loa loa infection should be ruled out in patients from endemic regions of Sub-Saharan Africa, before administration of ivermectin to prevent possible severe encephalopathy.

Given these considerations, a hybrid approach may be proposed, tailored on non-endemic setting, like Italy in order to mitigate the risk of Strongyloides hyperinfection or dissemination in patients hospitalized for COVID-19: (i) perform serology and, if possible, agar plate stool culture (or Baerman or PCR) on intermediate-risk subjects, such as autochthonous patients above 65 years old; (ii) consider presumptive treatment in high-risk groups, such as migrants from highly endemic regions and elderly Italian patients with eosinophil count superior to 500/mcL.

Even this approach require access to serological assay, now available only in a few tertiary or teaching hospitals, to be spread out across peripheral health centers. Indeed, serological screening for Strongyloides in newly arrived migrants has already been recommended by national guidelines, without implementation at a regional level [16] , probably due to budget limitations and low awareness about life-threatening consequences of the disease. Hopefully, as already mentioned by Tilli M et al., COVID-19 pandemic could become an opportunity to resume and strengthen screening policies about strongyloidiasis and other neglected tropical diseases in non endemic countries [17] .

Strongyloides infection manifested during immunosuppressive therapy for SARS-CoV-2 pneumonia. Infection

Dexamethasone in hospitalized patients with Covid-19-preliminary report

Interleukin-6 receptor antagonists in critically ill patients with Covid-19-preliminary report

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions

Recommendations for infectious disease screening in migrants to Western Europe with inflammatory arthropathies before starting biologic agents. Results from a multidisciplinary task force of four European societies (SIR, SER, SIMET, SEMTSI) facing the lar

Disseminated strongyloidiasis arising from a single dose of dexamethasone before stereotactic radiosurgery

Case report: disseminated strongyloidiasis in a patient with COVID-19

Epidemiology of Strongyloides stercoralis in northern Italy: Results of a multicentre case-control study

Prevalence of strongyloidiasis and schistosomiasis among migrants: a systematic review and meta-analysis

Seroprevalence of five neglected parasitic diseases among immigrants accessing five infectious and tropical diseases units in Italy: a cross-sectional study

Evidence-based guidelines for screening and management of strongyloidiasis in non-endemic countries

COVID-19 and dexamethasone: a potential strategy to avoid steroid-related strongyloides hyperinfection

Recommendations for management of endemic diseases and travel medicine in solid-organ transplant recipients and donors: Latin America

Neglected tropical diseases in Europe: rare diseases and orphan drugs?

Health assessment for migrants and asylum seekers upon arrival and while hosted in reception centres: Italian guidelines

Neglected tropical diseases in non-endemic countries in the era of COVID-19 pandemic: the great forgotten